Atlyphe
1 known investors
Zürich biotech developing targeted immunotherapy (ALY117) for stem cell transplantation and cancer.
Investors · 1
Frequently asked questions
- What does Atlyphe do?
- Zürich biotech developing targeted immunotherapy (ALY117) for stem cell transplantation and cancer.
- Who are Atlyphe's investors?
- Atlyphe's investors include Kickfund.